Curated News
By: NewsRamp Editorial Staff
June 18, 2024
Clene (NASDAQ: CLNN) CEO and CFO Present Corporate Updates and Future Plans at 72nd Emerging Growth Conference
Discuss on Reddit
Discuss on SubstackTLDR
- Clene is in negotiations to extend cash runway, potentially bringing in up to $130 million in additional capital
- CNM-Au8 has shown favorable safety profile, with over 650 collective years of subject exposure
- Clene's focus on improving mitochondrial health and treating neurodegenerative diseases has the potential to make tomorrow better than today
- Clene participated in the 72nd Emerging Growth Conference, presenting highlights and updates on the company's pipeline
Impact - Why it Matters
This news matters as it provides insight into Clene's progress in developing treatments for neurodegenerative diseases, potentially attracting investors and offering hope for patients with ALS and MS.
Summary
Clene's CEO Rob Etherington and CFO Morgan Brown presented highlights and updates on the company’s pipeline, including potential licensing deals and cash runway extension, at the 72nd Emerging Growth Conference. They also discussed the favorable safety profile of CNM-Au8 and ongoing clinical trials for ALS and MS.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene (NASDAQ: CLNN) CEO and CFO Present Corporate Updates and Future Plans at 72nd Emerging Growth Conference
